annual meeting program - American Society of Clinical Oncology

Monday, June 7, 2010
Brd. 4B Interleukin-2 (IL-2)-based immunotherapy for the treatment of metastatic
renal cell carcinoma (mRCC): An analysis of 422 consecutive patients treated
between 1999 and 2008. (Abstract #4591)
F. Donskov, H. K. Jensen, A. N. Jeppesen, K. Fode, H. Schmidt, M. Agerbaek,
L. Broendum, H. von der Maase
Brd. 4C Use of a nomogram to quantify overall survival (OS) benefit in patients with
metastatic renal cell carcinoma (mRCC) receiving bevacizumab (BEV) with
interferon (IFN) versus IFN alone. (Abstract #4592)
P. Karakiewicz, M. Sun, V. Sneller, B. Escudier
Brd. 4D Use of the UCLA Integrated Staging System (UISS) to predict survival after
sunitinib treatment for patients with metastatic renal cell carcinoma.
(Abstract #4593)
F. Pouliot, C. Anterasian, T. Klatte, D. Finley, B. Shuch, F. F. Kabbinavar,
N. Zomorodian, A. S. Belldegrun, A. J. Pantuck
Brd. 4E TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma
(mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferonalfa
(IFN-�). (Abstract #4594)
S. Patil, R. A. Figlin, T. E. Hutson, D. Michaelson, S. Negrier, S. T. Kim, X. Huang,
R. J. Motzer
Brd. 4F Overall survival (OS) of metastatic renal cell carcinoma (mRCC) patients
corrected for crossover using inverse probability of censoring weights
(IPCW) and rank preserving structural failure time (RPSFT) models: Two
analyses from the RECORD-1 trial. (Abstract #4595)
P. Korhonen, E. Malangone, S. Sherman, R. Casciano, R. J. Motzer, J. Baladi,
T. Haas, E. Zuber, A. C. Kay, D. E. Lebwohl
Brd. 4G Patient preferences for targeted agents in renal cell carcinoma (RCC): A
benefit–risk conjoint study. (Abstract #4596)
A. B. Hauber, A. F. Mohamed, F. R. Johnson, M. Neary
Brd. 4H Validation of a kinetic analysis of renal cancer regression and growth
following treatment with sunitinib and interferon-alfa (IFN-�): Analysis of the
pivotal randomized trial. (Abstract #4597)
J. Wilkerson, W. D. Stein, S. T. Kim, X. Huang, R. J. Motzer, A. T. Fojo, S. E. Bates
Brd. 5A Epidemiological trends in renal cell carcinoma (RCC) in the cytokine (CYT)
and targeted therapy (TT) eras: A registry analysis of 28,252 patients (pts).
(Abstract #4598)
D. W. Shek, M. Brown, C. Pan, P. Lara Jr.
Brd. 5B Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC):
Subgroup analysis from a phase II randomized discontinuation trial (RDT).
(Abstract #4599)
P. Bhargava, B. Esteves, M. Al-Adhami, D. Nosov, O. N. Lipatov, A. A. Lyulko,
A. A. Anischenko, R. T. Chacko, D. Doval, W. J. Slichenmyer
Brd. 5C Complete remission with TKI in renal cell carcinomas: Experience in 65
patients of the French Kidney Cancer Group. (Abstract #4600)
L. Albiges, S. Oudard, S. Negrier, A. Caty, G. Gravis, F. Joly, B. Duclos,
L. Geoffrois, F. Rolland, B. Escudier
Brd. 5D A clinical and biological profile to predict risk of development of
hypertension in patients with non-clear cell renal cell carcinoma treated with
sunitinib. (Abstract #4601)
N. A. Ilias-Khan, A. Y. Khakoo, N. M. Tannir
Brd. 5E Risk of congestive heart failure with VEGF-targeted therapy: A systematic
review and meta-analysis of clinical trials. (Abstract #4602)
F. A. Schutz, Y. Je, G. R. Azzi, T. K. Choueiri
Brd. 5F The safety and efficacy of sunitinib prior to planned nephrectomy in
metastatic clear cell renal cancer. (Abstract #4603)
T. Powles, I. Kayani, C. U. Blank, S. Chowdhury, S. Horenblas, N. Sarwar,
P. D. Nathan, E. Boleti, J. B. Haanen, A. Bex
361
MONDAY